Form 4: SCPH Director Sells All Shares Post-Merger

Director Jack A. Khattar disposed of all scPharmaceuticals Inc. common stock and stock options following the company's merger with MannKind Corporation.

Summary

• Director Jack A. Khattar reported changes in beneficial ownership of scPharmaceuticals Inc. securities.
• The transactions occurred on October 7, 2025, following the completion of a merger.
• Khattar disposed of 5,000 shares of common stock.
• He also disposed of 72,174 stock options with exercise prices ranging from $3.37 to $4.53.
• Following these transactions, Khattar beneficially owns 0 shares of common stock and 0 derivative securities.
• The disposition was due to scPharmaceuticals Inc. being acquired by MannKind Corporation.
• Shareholders received $5.35 in cash per share plus one non-tradable Contingent Value Right (CVR) for up to $1.00 per CVR.
• Stock options with an exercise price less than $5.35 were converted into a cash payment and CVRs.

Sentiment

Score: 7

Explanation: The filing reports the finalization of an acquisition, providing a cash exit and potential future value for shareholders. While it marks the end of scPharmaceuticals as an independent entity, the terms appear to be a structured exit for investors.

Positives

• The merger provided shareholders with a cash payment of $5.35 per share.
• Shareholders also received a Contingent Value Right (CVR) offering potential additional payments of up to $1.00 per CVR based on future milestones.
• Stock option holders with in-the-money options received cash and CVRs for their holdings.

Negatives

• scPharmaceuticals Inc. is no longer an independent publicly traded entity, becoming a wholly owned subsidiary of MannKind Corporation.
• The CVRs are non-tradable, limiting liquidity for the contingent payment component.
• The value of CVRs is contingent on future regulatory and net sales milestones, introducing uncertainty.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on the achievement of specific regulatory and net sales milestones.
• CVRs are non-tradable, meaning holders cannot sell them on the open market.
• Potential for applicable withholding taxes on both cash and CVR payments.

Future Outlook

The future outlook for scPharmaceuticals Inc. as an independent entity is concluded, as it has become a wholly owned subsidiary of MannKind Corporation. The future value for former shareholders holding CVRs depends on MannKind's ability to achieve specific regulatory and net sales milestones for scPharmaceuticals' products.

Management Comments

• Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ('CVR'), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash.
• Each option to purchase shares of Common Stock... that had an exercise price per share that was less than $5.35... was cancelled and converted into the right to receive (i) an amount in cash... equal to (A) the total number of shares subject to such Company Option... multiplied by (B) the excess... of (x) $5.35 over (y) the exercise price... and (ii) one CVR in respect of each share subject to such Company Option.

Industry Context

This filing reflects a consolidation event within the pharmaceutical or biotechnology industry, where a larger company (MannKind) acquires a smaller one (scPharmaceuticals) to potentially expand its product portfolio or market share. Such acquisitions are common strategies for growth and can provide an exit for investors in the acquired company.

Comparison to Industry Standards

• The acquisition price of $5.35 cash plus a CVR up to $1.00 per share is a specific deal term. Without details on scPharmaceuticals' financials or comparable acquisitions in the specialty pharmaceutical sector, a direct assessment against industry benchmarks is difficult.
• Acquisitions involving CVRs are a common mechanism in biotech/pharma to bridge valuation gaps and share future risks/rewards, particularly for assets with significant regulatory or commercial hurdles remaining. Companies like Pfizer, Bristol Myers Squibb, and Merck have utilized CVRs in past acquisitions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, ending their direct equity ownership in scPharmaceuticals Inc.
• Employees: Likely to be integrated into MannKind Corporation, with potential changes in roles or reporting structures.
• Management: Director Jack A. Khattar's directorship of the public entity effectively ended.
• Customers/Suppliers: Operations will continue under MannKind Corporation, potentially leading to integration of supply chains or sales channels.

Next Steps

• Former scPharmaceuticals Inc. shareholders holding CVRs will await the achievement of specified regulatory and net sales milestones for potential additional payments.
• MannKind Corporation will integrate scPharmaceuticals Inc. into its operations.

Key Dates

Keywords

scPharmaceuticals, SCPH, MannKind Corporation, Merger, Tender Offer, Form 4, Insider Transaction, Contingent Value Right, CVR, Acquisition, Stock Options, Director